iBio
IBIO
28 hedge funds and large institutions have $5.68M invested in iBio in 2024 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 3 increasing their positions, 11 reducing their positions, and 5 closing their positions.
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
0% more funds holding
Funds holding: 28 → 28 (0)
50% less capital invested
Capital invested by funds: $11.4M → $5.68M (-$5.75M)
51.68% less ownership
Funds ownership: 82.91% → 31.23% (-52%)
73% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 11
Top Buyers
| 1 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
+$518K |
| 2 |
BFM
Boothbay Fund Management
New York
|
+$343K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$106K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$83.4K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$77.4K |
Top Sellers
| 1 |
AC
Armistice Capital
New York
|
-$1.42M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$656K |
| 3 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$64.5K |
| 4 |
Renaissance Technologies
New York
|
-$64K |
| 5 |
SM
Sabby Management
Miami Beach,
Florida
|
-$56.8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AAP
26
Arax Advisory Partners
Denver,
Colorado
| $3 | – | – | – |
|
27
Wells Fargo
San Francisco,
California
| $2 | -$58 | -27 | -96% |
|
|
AC
28
Armistice Capital
New York
| – | -$1.42M | -350,877 | Closed |
|
|
29
Renaissance Technologies
New York
| – | -$64K | -15,879 | Closed |
|
|
SM
30
Sabby Management
Miami Beach,
Florida
| – | -$56.8K | -14,000 | Closed |
|
|
FIA
31
FNY Investment Advisers
New York
| – | -$36 | -9,000 | Closed |
|
32
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$32 | -15 | -29% |
|
33
Fidelity Investments
Boston,
Massachusetts
| – | -$16 | -4 | Closed |
|
IBIO Hedge Fund Activity: Q2 2024 in Review
28 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in iBio (IBIO) for Q2 2024, worth a combined $5.68M — down 50% from $11.4M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new IBIO positions and 5 closed out — a net gain of 1 holder — while 3 added to existing stakes and 11 trimmed.
The largest buyer was Lynx1 Capital Management, adding an estimated $518K. The largest seller was Armistice Capital, exiting entirely with an estimated $1.42M sold.
- 28 institutional investors held iBio (IBIO) as of Q2 2024, unchanged from Q1 2024.
- Funds reported $5.68M of iBio stock for Q2 2024, down 50% quarter-over-quarter.
- 6 funds opened new iBio positions in Q2 2024 and 5 closed out, a net change of +1 holder.
- The largest iBio buyer in Q2 2024 was Lynx1 Capital Management, an estimated $518K added.
- The largest iBio seller in Q2 2024 was Armistice Capital, an estimated $1.42M sold.
Based on aggregated 13F filings for Q2 2024.